Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects

NCT01620762 is registered in ClinicalTrials.gov with Circassia Limited as lead sponsor.

NCT NCT01620762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01620762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
Lead sponsor
Circassia Limited
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2012
Completion date
Not reported
Enrollment
1,408 (actual)
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

rhinoconjunctivitis